How close are we to customizing chemotherapy in early non-small cell lung cancer?

@article{Ioannidis2011HowCA,
  title={How close are we to customizing chemotherapy in early non-small cell lung cancer?},
  author={Georgios N Ioannidis and Vassilis Georgoulias and John Souglakos},
  journal={Therapeutic advances in medical oncology},
  year={2011},
  volume={3 4},
  pages={185-205}
}
Although surgery is the only potentially curative treatment for early-stage non-small cell lung cancer (NSCLC), 5-year survival rates range from 77% for stage IA tumors to 23% in stage IIIA disease. Adjuvant chemotherapy has recently been established as a standard of care for resected stage II-III NSCLC, on the basis of large-scale clinical trials employing third-generation platinum-based regimens. As the overall absolute 5-year survival benefit from this approach does not exceed 5% and… CONTINUE READING

Similar Papers

Loading similar papers…